We’ve seen tremendous progress in the field of cancer immunotherapy in recent years, and the potential now exists to improve on the benefits obtained with monotherapy by combining agents with complementary mechanisms of action.More than 800 trials of immune-based combination therapies are underway; coupled with increasing opportunities for collaboration between the pharmaceutical and biotech industries, government and academia, the field is at an exciting juncture where the potential for novel therapeutic approaches has never been greater.The Society for Immunotherapy of Cancer (SITC) Combination Immunotherapies Task Force has convened to:
The Combination Immunotherapies Task Force focus is upon the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer. Standardization of assays, assay validation, and appropriate potency assays were the subjects of one subcommittee while the other assessed the clinical utility of promising novel technologies and made recommendations on how to incorporate these into the clinical arena.
Patrick Ott, MD, PhD Dana-Farber Cancer Institute/Harvard Medical SchoolHolbrook Edwin Kidd Kohrt, MD, PhD (1977-2016)* Stanford Cancer Institute*Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC.
F. Stephen Hodi, MD Dana-Farber Cancer Institute
Howard L. Kaufman, MD, FACSReplimune Group Inc.
Jon M. Wigginton, MD MacroGenics, Inc.
Jedd D. Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center
Journal for ImmunoTherapy of Cancer, February 2017
By summarizing the current status of combination immunotherapy, and addressing potential challenges in development and clinical implementation of combinatorial approaches, this paper provides evidence-based guidance to drive progress and improve on the clinical benefits obtained with single therapeutic agents. With greater understanding of the mechanisms of action of immunotherapy agents, and of the counter-defenses mounted by tumors, there is potential for novel combinations to increase the number of patients who respond to immunotherapy, the tolerability of treatment, and the duration of treatment response.
Dear All, I'll be attending SITC 2019 on November 7-8 and would like to network with anyone interested in or studying these topics. I'm new to the field of IO therapy and would appreciate any help making connections. Thanks, Rick ------------------------------ ...
Princeton Center for Theoretical Science presents the 2019 Distinguished Visiting Lecturer
Laboratoire de Physique Théorique Ecole Normale Supérieure Public Lecture : "The Evolution Within Us: Statistics of Immunity" ...
2019 Annual Cancer Treatment-Related Adverse Events Symposium
Friday-Saturday, October 25-26, 2019 Memorial Sloan Kettering Cancer Center Register online: http://www.mskcc.org/AdverseEvents
Systemic anticancer therapies (cytotoxic ...
I would like to personally invite you to join Kim Margolin, MD, Ahmad Tahini, MD, PhD, and myself for SITC Webinar: I-O Highlights from ASCO 2019 , a free SITC webinar on Aug. 28 at Noon EDT where we discuss the latest advances ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com